Clik here to view.
Ireland Attracts Investments By Pfizer, Merck; But No Good News From Spain
The U.S. pharmaceutical industry has been kind to Ireland and its Taoiseach (Prime Minister) Enda Kenny this week. It has announced investments of more than Euro300 million ($400 million) in the...
View ArticleClik here to view.
Success Of German Cost-Control Law Raises Prospect Of Further Cuts For Pharma
Germany's pharmaceutical sector restructuring law (AMNOG) is living up to the government's expectations by putting the brakes on the country's drug expenditure.
View ArticleClik here to view.
Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control...
The Swedish government published on Sept. 22 a framework directive designed to revolutionize the pricing, reimbursement of and access to patent-protected pharmaceuticals. The directive appoints a...
View ArticleClik here to view.
Teva Launches Generic Salmeterol in the U.K. To Compete With GSK's Serevent
Teva Pharmaceuticals Industries Ltd. has succeeded in piercing the market exclusivity surrounding GlaxoSmithKline PLC's inhaled asthma products with a "first-to-market" launch on Oct.7 in the U.K. of a...
View ArticleClik here to view.
Lacking Mediator EC Tightens Pharmacovigilance Proposals
The biggest changes in the European Commission's revised proposals on how pharmaceutical manufacturers can provide information to patients don't have to do with communications to patients at all - they...
View ArticleClik here to view.
Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under...
Merck KGaA's pharmaceuticals division, Merck Serono, has returned global rights to the late-stage Parkinson's disease therapy safinamide to the Italian biotech Newron Pharmaceuticals SPA. The surprise...
View ArticleClik here to view.
Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce
Amsterdam Molecular Therapeutics BV's potential gene therapy, Glybera (alipogene tiparvovec), may have been rejected for approval by Europe's top scientific advisory panel, CHMP, on Oct. 21, but the...
View ArticleClik here to view.
Invitation to Innovative Drug R&D in Russia Forum
Adam Smith Conferences’ Innovative Drug R&D in Russia Forum will take place on 21-22 November in Moscow. This years’ Forum is set to become the one industry gathering that you cannot afford to...
View ArticleClik here to view.
Rx Class Action Suits May Come To France In Response To Mediator Scandal
A bill in the French upper house of parliament, the Senate, aimed at averting conflicts of interest in the pharmaceutical sector now has a section that could in fact encourage conflict by creating...
View ArticleClik here to view.
French Pharma Industry Pays The Price For Country’s Financial Woes
In an effort to shore up its credit rating, the French government has turned the financial screw on pharmaceutical manufacturers.
View ArticleClik here to view.
The End of The Euro: What Might It Mean For Pharma?
Companies struggle on how even to begin assessing impact of a possible Euro break-up.
View ArticleClik here to view.
The End of The Euro: What Might It Mean For Pharma?
Companies struggle on how even to begin assessing impact of a possible Euro break-up.
View ArticleClik here to view.
Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain
There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.
View ArticleClik here to view.
AZ’s Brillinta Is First Drug To Clear AMNOG Assessment, While Merck’s...
Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.
View ArticleClik here to view.
AZ’s Brillinta Is First Drug To Clear AMNOG Assessment, While Merck’s...
Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.
View ArticleClik here to view.
Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug...
German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.
View ArticleClik here to view.
U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details...
Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.
View ArticleClik here to view.
Austerity Holds Back VC Investing in European Biotech Companies in 2011
Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.
View ArticleClik here to view.
For Novartis, 2012 Is Set To Be A Bumpy Ride
With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.
View ArticleClik here to view.
European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical...
It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses.
View Article
